1: PRESERVING RESIDUAL RENAL FUNCTION
PD patients averaged 30% higher rGFR than HD patients over a 12-month period (P<.0001).1
2: IMPROVED EARLY SURVIVAL RATES
PD has shown improved survival within the first year compared with HD.2
3: REDUCED COVID-19 HOSPITALIZATIONS
The rate of COVID-19 hospitalizations among patients undergoing hemodialysis was between 3 and 4 times higher than among patients performing peritoneal dialysis.3
4: PATIENT SATISFACTION
PD patients have an 85% higher likelihood of excellent satisfaction vs HD patients.480% of ESRD patients are medically eligible for PD5 and 50% choose PD over HD when balanced choices are provided.6
5: COST-EFFECTIVE THERAPY
Average annual cost of supporting chronic dialysis for a PD patient is $34,300 as compared to an ICHD patients is $39,935.7 The ESRD Treatment Choices Model now offers additional reimbursement for nephrologists and dialysis clinics for the use of home therapies, including PD.
Call 1-800-284-4060 for your local Baxter representative who can provide resources that help you grow your PD program.
Click on links below to discover Why PD with Baxter